These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
222 related articles for article (PubMed ID: 15709279)
1. Access to medicines and the rhetoric of responsibility. Barry C; Raworth K Ethics Int Aff; 2002; 16(2):57-70. PubMed ID: 15709279 [No Abstract] [Full Text] [Related]
2. Some questions about the moral responsibilities of drug companies in developing countries. Brock DW Dev World Bioeth; 2001 May; 1(1):33-7. PubMed ID: 12870506 [No Abstract] [Full Text] [Related]
3. Intellectual property and pharmaceutical drugs: an ethical analysis. De George RT Bus Ethics Q; 2005 Oct; 15(4):549-75. PubMed ID: 16358442 [TBL] [Abstract][Full Text] [Related]
4. Social responsibility and global pharmaceutical companies. Daniels N Dev World Bioeth; 2001 May; 1(1):38-41. PubMed ID: 12870507 [No Abstract] [Full Text] [Related]
5. Introduction: ethical responsibilities regarding drugs, patents, and health. Ryan MP Bus Ethics Q; 2005 Oct; 15(4):543-7. PubMed ID: 16358441 [No Abstract] [Full Text] [Related]
6. TRIPS, pharmaceutical patents, and access to essential medicines: a long way from Seattle to Doha. 't Hoen E Chic J Int Law; 2002; 3(1):27-46. PubMed ID: 15709298 [No Abstract] [Full Text] [Related]
7. Tripping over patents: AIDS, access to treatment and the manufacturing of scarcity. Berger JM Conn J Int Law; 2002; 17(2):157-248. PubMed ID: 12688292 [No Abstract] [Full Text] [Related]
8. The missing ingredient in medicine patent pools. Gold ER; Morin JF Lancet; 2009 Oct; 374(9698):1329-30. PubMed ID: 19837251 [No Abstract] [Full Text] [Related]
9. In the high court of South Africa, case no. 4138/98: the global politics of access to low-cost AIDS drugs in poor countries. Barnard D Kennedy Inst Ethics J; 2002 Jun; 12(2):159-74. PubMed ID: 12476916 [TBL] [Abstract][Full Text] [Related]
11. Access to medicines in developing countries: ethical demands and moral economy. Cassier M; Correa M Dev World Bioeth; 2014 Aug; 14(2):ii-viii. PubMed ID: 25039326 [No Abstract] [Full Text] [Related]
12. South Africa's moral victory. Lancet; 2001 Apr; 357(9265):1303. PubMed ID: 11343727 [No Abstract] [Full Text] [Related]
13. Questions raised about whether compulsory licenses get best prices. Owens B Nat Med; 2015 Apr; 21(4):300. PubMed ID: 25849264 [No Abstract] [Full Text] [Related]
14. Intellectual property rights, the World Trade Organization and public health: the Brazilian perspective. Viana JM Conn J Int Law; 2002; 17(2):311-8. PubMed ID: 12688298 [No Abstract] [Full Text] [Related]
15. Essential AIDS medications in India. Thomas J Issues Med Ethics; 2000; 8(2):62. PubMed ID: 16323350 [No Abstract] [Full Text] [Related]
16. Ensuring new medicines reach those in most need. Burrone E; Perry G Lancet HIV; 2015 Sep; 2(9):e362-3. PubMed ID: 26423544 [No Abstract] [Full Text] [Related]
17. The dilemma of intellectual property rights for pharmaceuticals: the tension between ensuring access of the poor to medicines and committing to international agreements. Cohen JC; Illingworth P Dev World Bioeth; 2003 May; 3(1):27-48. PubMed ID: 14577451 [TBL] [Abstract][Full Text] [Related]
18. An unequal activism for an unequal epidemic? Selemogo M Dev World Bioeth; 2005 May; 5(2):153-68. PubMed ID: 15842724 [TBL] [Abstract][Full Text] [Related]
19. Access to treatment for HIV/AIDS: a human rights issue in the developing world. Joni J Conn J Int Law; 2002; 17(2):273-80. PubMed ID: 12688296 [No Abstract] [Full Text] [Related]
20. Introduction: Pharmaceutical firms and the right to health. de Campos TC; Pogge T J Law Med Ethics; 2012; 40(2):183-7. PubMed ID: 22789038 [No Abstract] [Full Text] [Related] [Next] [New Search]